The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and availability of oral valganciclovir(VGC) at the does of
450mg daily begin within 10 days after renal transplantation, and till to Day 100
posttransplant. Compare to the guidelines for effective antiviral prophylaxis, the
investigators divide these patients into three groups in random. One third will oral VGC
450mg daily as mentioned above; one third will oral VGC 900mg daily; and the other one third
will intravenous GCV 5mg/kg daily within the first 14 days posttransplant, and continue to
oral GCV 1g 3 times daily till to Day 100 posttransplant; with does adjusted per renal
function for all agents.
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University